2021
1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Heumann T, Baretti M, Sugar E, Durhman J, Liden S, Miles T, Lopez-Vidal T, Leatherman J, Sharma A, Ahuja N, Weekes C, O'Dwyer P, Monga D, Binder K, Azad N. 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals Of Oncology 2021, 32: s1087-s1088. DOI: 10.1016/j.annonc.2021.08.797.Peer-Reviewed Original Research
2016
IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers
Fu T, Pappou EP, Guzzetta AA, de Freitas Calmon M, Sun L, Herrera A, Li F, Wolfgang CL, Baylin SB, Iacobuzio-Donahue CA, Tong W, Ahuja N. IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers. Annals Of Surgery 2016, 263: 337-344. PMID: 25822686, PMCID: PMC4648704, DOI: 10.1097/sla.0000000000001204.Peer-Reviewed Original ResearchConceptsStage II colorectal cancerRisk of recurrenceIGFBP-3 methylationLymph nodesColorectal cancerHazard ratioPrimary tumorHigh riskIndependent cohortFive-year recurrence-free survival ratesRecurrence-free survival ratesHigh-risk patientsSignificant prognostic factorsIdentification of patientsProportional hazards modelIGFBP-3Prognostic factorsTumor characteristicsPredicts RecurrenceHazards modelPatientsRecurrenceSurvival rateMultivariate analysisSurgery
2015
A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence.
Reiss K, Ahuja N, Baylin S, Mauro L, Linden S, White S, Laheru D, Herman J, Wolfgang C, Weiss M, Cameron J, Makary M, Azad N. A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence. Journal Of Clinical Oncology 2015, 33: tps4144-tps4144. DOI: 10.1200/jco.2015.33.15_suppl.tps4144.Peer-Reviewed Original Research
2014
Liver transplant patients have a risk of progression similar to that of sporadic patients with branch duct intraductal papillary mucinous neoplasms
Lennon AM, Victor D, Zaheer A, Ostovaneh MR, Jeh J, Law JK, Rezaee N, Dal Molin M, Ahn YJ, Wu W, Khashab MA, Girotra M, Ahuja N, Makary MA, Weiss MJ, Hirose K, Goggins M, Hruban RH, Cameron A, Wolfgang CL, Singh VK, Gurakar A. Liver transplant patients have a risk of progression similar to that of sporadic patients with branch duct intraductal papillary mucinous neoplasms. Liver Transplantation 2014, 20: 1462-1467. PMID: 25155689, PMCID: PMC4322915, DOI: 10.1002/lt.23983.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmHigh-risk featuresBranch-duct intraductal papillary mucinous neoplasmsLiver transplant patientsRisk of progressionBD-IPMNsPapillary mucinous neoplasmLT patientsLT recipientsTransplant patientsMucinous neoplasmsControl groupManagement of patientsHistory of immunosuppressionHigh-grade dysplasiaControl patientsSurgical resectionBD-IPMNConsecutive patientsExtrahepatic malignanciesMedian lengthMalignant potentialHigh riskPatientsSporadic patientsRole of a Multidisciplinary Clinic in the Management of Patients with Pancreatic Cysts: A Single-Center Cohort Study
Lennon AM, Manos LL, Hruban RH, Ali SZ, Fishman EK, Kamel IR, Raman SP, Zaheer A, Hutfless S, Salamone A, Kiswani V, Ahuja N, Makary MA, Weiss MJ, Hirose K, Goggins M, Wolfgang CL. Role of a Multidisciplinary Clinic in the Management of Patients with Pancreatic Cysts: A Single-Center Cohort Study. Annals Of Surgical Oncology 2014, 21: 3668-3674. PMID: 24806116, PMCID: PMC4332823, DOI: 10.1245/s10434-014-3739-x.Peer-Reviewed Original ResearchConceptsManagement of patientsPancreatic cystsSurgical resectionBranch-duct intraductal papillary mucinous neoplasmsSingle-center cohort studyIntraductal papillary mucinous neoplasmRisk categoriesPapillary mucinous neoplasmTypes of cancerCohort studyMultidisciplinary careCommon diagnosisMultidisciplinary clinicMucinous neoplasmsMalignant cystsHigh riskPatientsPatient careFurther evaluationCystsDiagnosisResectionClinicDifferent risksInstitution's recordsCpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas
Sun L, Guzzetta AA, Fu T, Chen J, Jeschke J, Kwak R, Vatapalli R, Baylin SB, Iacobuzio-Donahue CA, Wolfgang CL, Ahuja N. CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas. Epigenetics 2014, 9: 738-746. PMID: 24518818, PMCID: PMC4063833, DOI: 10.4161/epi.28082.Peer-Reviewed Original ResearchConceptsCpG island methylator phenotypeSporadic duodenal adenomasDuodenal adenomasBRAF mutationsVillous typeMethylator phenotypeCIMP-high statusPeriampullary locationAggressive managementDuodenal adenocarcinomaClinicopathologic featuresColorectal cancerColorectal adenomasKRAS mutationsHigh riskAdenomasMLH1 methylationCIMP statusCancerous lesionsOlder ageP16 methylationTumorsMalignancyInfrequent eventRole of methylation